Advertisement
Advertisement

PYXS

PYXS logo

Pyxis Oncology, Inc. Common Stock

1.35
USD
Sponsored
-0.14
-9.06%
Mar 05, 15:58 UTC -5
Closed
exchange

Pre-Market

1.41

+0.06
+4.15%

PYXS Earnings Reports

Positive Surprise Ratio

PYXS beat 7 of 17 last estimates.

41%

Next Report

Date of Next Report
Mar 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.34
Implied change from Q-- -- (Revenue/ EPS)
--
/
--
Implied change from Q4 24 (Revenue/ EPS)
--
/
+36.00%

Pyxis Oncology, Inc. Common Stock earnings per share and revenue

On --, PYXS reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 11 analysts forecast an EPS of -0.34 USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Harrow, Inc. Common Stock
Report Date
Mar 02, 2026 For Q4 25
Estimate
$0.37
Actual
$0.26
Surprise
-30.87%
logo
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Mar 03, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.30
Surprise
+18.50%
logo
Bioventus Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.21
Actual
$0.24
Surprise
+9.69%
logo
Altimmune, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.24
Actual
-$0.27
Surprise
-10.16%
logo
Aquestive Therapeutics, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.26
Surprise
-92.31%
logo
OmniAb, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.11
Surprise
-21.82%
logo
Profound Medical Corp. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.27
Surprise
-0.26%
logo
MediWound Ltd.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.56
Surprise
+13.08%
logo
Cumberland Pharmaceuticals Inc
Report Date
Mar 03, 2026 For Q4 25
Estimate
-
Actual
-$0.01
Surprise
-
logo
Stevanato Group S.p.A.
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.17
Actual
$0.18
Surprise
+4.55%
FAQ
For Q-- --, Pyxis Oncology, Inc. Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for Mar 25, 2026.
Based on 11 analysts, Pyxis Oncology, Inc. Common Stock is expected to report EPS of -$0.34 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement